Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 48Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Non-Small-Cell Lung 15Neoplasms 11Head and Neck Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 8Pancreatic Neoplasms 7Colonic Neoplasms 7Carcinoma, Squamous Cell 7Solid Tumors 5Rectal Neoplasms 4Ovarian Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Melanoma 2Locally Recurrent Rectal Cancer 2Carcinoma, Pancreatic Ductal 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1

Interventions

Radiotherapy 2tislelizumab 1pembrolizumab 1TP protocol 1Paclitaxel 1Lomustine 1Cisplatin 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Recurrence, Local × Cetuximab × Clear all
NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

Phase 1 Recruiting
36 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡